Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.

Daniel E Lage M Dror MichaelsonRichard J LeeJoseph A GreerJennifer S TemelChristopher J Sweeney

Published in: Prostate cancer and prostatic diseases (2021)

Older men with mHSPC had similar OS benefit and clinical outcomes compared to younger men when receiving docetaxel + ADT. Oncologists should consider docetaxel chemotherapy as a favorable treatment option for older men with mHSPC who are fit for chemotherapy.

Keyphrases

middle aged
locally advanced
prostate cancer
community dwelling
physical activity
squamous cell carcinoma
small cell lung cancer
rectal cancer
radiation therapy
type diabetes
metabolic syndrome
skeletal muscle
adipose tissue